Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

NCT02455297 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Mantle-Cell

Interventions

DRUG: Copanlisib (BAY80-6946)

Sponsor

Bayer